Fused pyrimidinone compounds as mglur ligands
OwnerRalf Glatthar, Samuel Hintermann +1inventors
InventorsRalf Glatthar, Samuel Hintermann, Ivan-Toma Vranesic
Life of this patent
Estimating the term…
Abstract
The invention relates to compounds of Formula (I) wherein the substituents are as defined in claim 1; to compositions comprising said compounds and to their use as pharmaceutical agents.
Claims18
A compound of formula (I) or a tautomeric form thereof
- wherein
- U represents C or N;
- V represents CH, N, or O;
- W represents C, N, or O;
- R1 represents an optionally substituted aryl or an optionally substituted heteroaryl group;
- R2 if present is selected from the group consisting of H, alkyl, aryl, hydroxy or alkoxy;
- R3 is selected from the group consisting of optionally substituted cycloalkyl, optionally substituted heterocycloalkyl or 3-Cl-phenyl;
- in free base or acid addition salt form,
- with the proviso, that the compound of the formula
- is excluded.
13-18. (canceled)
A method of treating, preventing or delaying the progression of a disorder associated with irregularities of the glutamatergic signal transmission of the gastrointestinal or urinary tract or a nervous system disorders mediated full or in part by mGluR group I receptors, comprising administering to a subject a compound represented of formula (I) or a tautomeric form thereof
- wherein
- U represents C or N;
- V represents CH, N, or O;
- W represents C, N, or O;
- R1 represents an optionally substituted aryl or an optionally substituted heteroaryl group;
- R2 if present is selected from the group consisting of H, alkyl, aryl, hydroxy or alkoxy;
- R3 is selected from the group consisting of optionally substituted cycloalkyl, optionally substituted heterocycloalkyl or 3-Cl-phenyl;
- in free base or acid addition salt form.
Dependencies are inferred from the claim text.